References
- Balko JM, Schwarz LJ, Luo N, Estrada MV, Giltnane JM, Davila-Gonzalez D, et al. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. Sci Transl Med 2016 Apr 13; 8(334):334ra53; PMID:27075627; http://dx.doi.org/10.1126/scitranslmed.aad3001
- Barrett MT, Anderson KS, Lenkiewicz E, Andreozzi M, Cunliffe HE, Klassen CL, et al. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget 2015 Sep 22; 6(28):26483-93; PMID:26317899; http://dx.doi.org/10.18632/oncotarget.4494
- Rui L, Emre NC, Kruhlak MJ, Chung HJ, Steidl C, Slack G, et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2010 Dec 14; 18(6):590-605; PMID:21156283
- Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010 Oct 28; 116(17):3268-77;PMID:20628145; http://dx.doi.org/10.1182/blood-2010-05-282780
- Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, et al. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. J Clin Oncol 2016 Apr 11; PMID:2706908; http://dx.doi.org/10.1200/JCO.2016.66.4482
- Hao Y, Chapuy B, Monti S, Sun HH, Rodig SJ, Shipp MA. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. Clin Cancer Res [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2014 May 15; 20(10):2674-83; PMID:24610827; http://dx.doi.org/10.1158/1078-0432.CCR-13-3007
- Andraos R, Qian Z, Bonenfant D, Rubert J, Vangrevelinghe E, Scheufler C, et al. Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. Cancer Discov 2012 Jun; 2(6):512-23; PMID:22684457; http://dx.doi.org/10.1158/2159-8290.CD-11-0324
- Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F, et al. CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer Cell [Research Support, N.I.H., Extramural]. 2015 Jul 13; 28(1):15-28; PMID:26175413; http://dx.doi.org/10.1016/j.ccell.2015.06.006
- Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood [Letter]. 2013 Nov 28; 122(23):3843-4; PMID:24288410; http://dx.doi.org/10.1182/blood-2013-10-531103
- Gotthardt D, Putz EM, Grundschober E, Prchal-Murphy M, Straka E, Kudweis P, et al. STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion. Cancer Discov 2016 Apr; 6(4):414-29; PMID:26873347; http://dx.doi.org/10.1158/2159-8290.CD-15-0732